CAR T-Cell Therapy: Eligibility, Indications, and Potential Benefits for Blood Cancers

Chimeric Antigen Receptor (CAR) T-cell therapy is a revolutionary immunotherapy that engineers a patient's own T cells to recognize and attack cancer cells. It has transformed outcomes for certain relapsed/refractory hematologic malignancies.

FDA-Approved Indications (as of 2024)

• B-cell acute lymphoblastic leukemia (B-ALL): Relapsed/refractory (R/R) in patients ≤25 years (tisagenlecleucel); R/R adult (brexucabtagene autoleucel)
• Large B-cell lymphoma (LBCL): R/R after ≥2 lines (DLBCL, PMBCL, transformed FL, HGBCL) — axicabtagene ciloleucel, tisagenlecleucel, lisocabtagene maraleucel
• Follicular lymphoma (FL): R/R after ≥2 lines — tisagenlecleucel, axicabtagene ciloleucel
• Mantle cell lymphoma (MCL): R/R after ≥2 lines (including BTK inhibitor) — brexucabtagene autoleucel
• Multiple myeloma: R/R after ≥4 lines (including PI, IMiD, anti-CD38) — idecabtagene vicleucel, ciltacabtagene autoleucel

General Eligibility Criteria

• Confirmed diagnosis matching approved indication
• Relapsed or refractory to standard therapies (number of prior lines per indication)
• Adequate organ function: cardiac (LVEF ≥45–50%), hepatic, renal, pulmonary
• Performance status: ECOG 0–1 (some trials allow 2)
• No uncontrolled infection, active hepatitis B/C, HIV with uncontrolled viremia
• No recent major surgery, stroke, or significant cardiovascular event
• Adequate T-cell collection (leukapheresis) feasibility
• No prior allogeneic transplant (autologous CAR-T); some trials explore allogeneic

High-Risk / Aggressive Disease Considerations

Patients with high-tumor-burden, rapid progression, or high-risk cytogenetics may be considered on a case-by-case basis. Bridging therapy (radiation, steroids, low-dose chemo) often used during manufacturing (3–5 weeks) to control disease.

Potential Benefits

• Deep, durable remissions in heavily pretreated patients
• Complete response (CR) rates: 30–50%+ in LBCL; 60–80%+ in myeloma
• Long-term remission possible: Plateauing survival curves suggest cure fraction
• Finite treatment (single infusion) vs. continuous therapy

Key Risks and Toxicities

• Cytokine Release Syndrome (CRS): Fever, hypotension, hypoxia, organ dysfunction (Grade 1–4); managed with tocilizumab ± steroids
• Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS): Confusion, aphasia, tremor, seizures, cerebral edema; graded 1–4
• Cytopenias: Prolonged neutropenia, thrombocytopenia
• Infections: Bacterial, viral, fungal (prolonged immune suppression)
• Hypogammaglobulinemia: B-cell aplasia → IVIG replacement
• Secondary malignancies: Rare T-cell lymphomas reported; FDA investigating

Decision Process

Made by a multidisciplinary team (hematology/oncology, cellular therapy, pharmacy, neurology, ICU) weighing overall health, disease biology, prior treatments, social support, and goals of care. Referral to an authorized CAR-T center (FACT-accredited) is required.

CAR T-cell therapy offers unprecedented hope for patients who have exhausted conventional options. If you or a loved one has a qualifying blood cancer, ask your oncologist about referral for evaluation.